5 results on '"Dou, Xiaoguang"'
Search Results
2. [A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status].
- Author
-
Long L, Liu Y, Duan Z, Xu Q, Shen T, Dou X, Zhuang H, and Lu F
- Subjects
- Adult, CD4 Lymphocyte Count, China epidemiology, Coinfection immunology, Coinfection virology, Female, Genotype, HIV Infections immunology, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C virology, Humans, Male, Middle Aged, RNA, Viral blood, Serologic Tests, Viral Load, Hepatitis C immunology, Hepatitis C Antibodies blood
- Abstract
Objective: To investigate the potential of hepatitis C virus (HCV) antibody measurement as a clinical approach to determine the infection status and potential for spontaneous-resolution among patients with HCV mono-infection and HCV/human immunodeficiency virus (HIV) co-infection., Methods: A total of 340 individuals who tested positive for serum anti-HCV antibodies and/or serum anti-HW antibodies were enrolled for study in 2009 from a single village in central China. Markers of liver function (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and infection (anti-HCV antibodies, CD4⁺ T cell counts, HCV genotype, and HCV viral load) were measured at baseline and follow-up (in July 2012). At follow-up,the subjects were grouped according to ongoing HCV mono-infection (n=129), ongoing HCV/HIV co-infection (n=98), spontaneously resolved (SR)-HCV in mono-infection (n=65), and SR-HCV in HCV/HIV co-infection (n=48) for statistical analysis., Results: Almost all of the subjects in the ongoing HCV mono-infection group showed high levels of HCV antibodies (S/CO more than or equal to 10), but the majority of the subjects in the SR-HCV in mono-infection group and in the ongoing HCV/HIV co-infection group. The SR-HCV mono-infection group showed a remarkable decrease in HCV antibodies from 2009 (HIV:7.75 ± 3.8; HIV+:7.61 ± 3.47) to 2012 (HIV:5.51 ± 3.67; HIW:4.93 ± 3.35) (HIV:t =10.67, P less than 0.01; HIV+:t =9.52, P less than 0.01). The ongoing HCV/HIV co-infection group showed a positive correlation between HCV antibodies S/CO ratio and CD4⁺ T cell count (r=028, P=0.008). In the ongoing HCV mono-infection group,the levels of HCV antibodies were significantly higher in individuals infected with HCV-1b than in those with HCV-2a (14.74 ± 1.68 vs.14.08 ± 1.44, t=2.20, P=0.03). In the ongoing HCV/HIV co-infection group, the numbers of subjects with elevated (more than 40 U/L) liver function markers were significantly different according to the HCV genotype infection:HCV-1b:ALT, 25/42 vs.16/56 (x²=9.45, P=0.002); HCV2a:AST, 28/42 vs.18/56 (x²=11.49, P=0.001). The HCV RNA positive rate was significantly higher in subjects with high HCV antibody cutoff values (S/CO more than or equal to 10) than in those with low HCV antibody (S/CO less than 10) (HIV:128/151 vs.1/43, x²=102.11, P less than 0.01; HIV+:88/98 vs.10/48, x²=69.44, P less than 0.01), regardless of HIV co-infection. Significantly more subjects in the ongoing HCV mono-infection group had elevated (more than 40 U/L) ALT or AST than the subjects in the SR-HCV mono-infection group with high levels of HCV antibody (S/CO more than or equal to 10) (ALT:57/128 vs.2/23, x²=10.52, P=0.001; AST:57/128 vs.0/23, x²=16.45, P less than 0.01)., Conclusion: Serum HCV antibody levels, in combination with other clinical information such as liver function and HIV infection status, may aid in the preliminarily evaluation of an individual's HCV infection status and likelihood for spontaneous resolution. Low levels of HCV antibody (S/CO less than 10) may indicate a better chance of SR-HCV, after ruling out the possibility of suffering from immunosuppressive diseases such as HIV infection.
- Published
- 2014
- Full Text
- View/download PDF
3. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.
- Author
-
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, and Negro F
- Subjects
- Asia epidemiology, Australia epidemiology, Egypt epidemiology, Genotype, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C prevention & control, Hepatitis C therapy, Hepatitis C transmission, Humans, Prevalence, Risk Assessment, Risk Factors, Time Factors, Hepatitis C epidemiology, Pandemics
- Abstract
Background: The hepatitis C pandemic has been systematically studied and characterized in North America and Europe, but this important public health problem has not received equivalent attention in other regions., Aim: The objective of this systematic review was to characterize hepatitis C virus (HCV) epidemiology in selected countries of Asia, Australia and Egypt, i.e. in a geographical area inhabited by over 40% of the global population., Methodology: Data references were identified through indexed journals and non-indexed sources. In this work, 7770 articles were reviewed and 690 were selected based on their relevance., Results: We estimated that 49.3-64.0 million adults in Asia, Australia and Egypt are anti-HCV positive. China alone has more HCV infections than all of Europe or the Americas. While most countries had prevalence rates from 1 to 2% we documented several with relatively high prevalence rates, including Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%). Nosocomial infection, blood transfusion (before screening) and injection drug use were identified as common risk factors in the region. Genotype 1 was common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 was found in Vietnam and other Southeast Asian countries. In India and Pakistan genotype 3 was predominant, while genotype 4 was found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria., Conclusion: We recommend implementation of surveillance systems to guide effective public health policy that may lead to the eventual curtailment of the spread of this pandemic infection., (© 2011 John Wiley & Sons A/S.)
- Published
- 2011
- Full Text
- View/download PDF
4. 难治性丙型肝炎再认识—谈丙型肝炎抗病毒治疗策略的进展
- Author
-
DOU Xiaoguang
- Subjects
hepatitis C ,antiviral agents ,reviews ,virus diseases ,lcsh:Diseases of the digestive system. Gastroenterology ,lcsh:RC799-869 - Abstract
It has been nearly 20 years from the discovery of hepatitis C virus (HCV) and clinical diagnosis of hepatitis C to antiviral therapy with interferon, and significant progress has been made. Substantial changes have taken place in both the concept and strategy for antiviral treatment of hepatitis C, with more and more direct-acting antiviral agents emerging in recent years; these changes are as follows: from the control of HCV to clinical cure, from a sustained virologic response (SVR) rate around 30% with conventional interferon therapy to an SVR rate of 70-80% with standard therapy with pegylated interferon and ribavirin, and from evaluating the difficulty of treatment based on genotypes and viral load to determining the treatment strategy according to host IL28B genotypes and response patterns (rapid virologic response and complete early virologic response). The progress in antiviral therapy strategies for hepatitis C is systematically reviewed for re-understanding of refractory hepatitis C.
- Published
- 2014
5. Expert interpretation of the "KASL Clinical Practice Guidelines: Management of hepatitis C".
- Author
-
DING Yang and DOU Xiaoguang
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.